Drug intelligence / Profile preview

bivalent recombinant covid-19 vaccine (adenovirus type 5 vector)

Development stage: Unknown
Lead developer: CanSino Biologics
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal, Intramuscular

Overview

A vaccine that uses adenovirus type 5 (Ad5) as a vector to deliver genetic material encoding SARS-CoV-2 spike proteins. This bivalent vaccine is designed to generate immune responses against multiple variants of the SARS-CoV-2 virus. It can be administered through different routes, including intranasal and intramuscular immunization, and is designed to induce both humoral and cellular immune responses.

Other names: universal recombinant adenovirus type-5 vaccine against COVID-19Ad5-nCoVAd-5-nCoVAd 5-nCoV

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on bivalent recombinant covid-19 vaccine (adenovirus type 5 vector).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bivalent recombinant covid-19 vaccine (adenovirus type 5 vector).

Explore the full profile